Get started
Markets US Stocks Health Technology Pharmaceuticals: Major

Akero Therapeutics, Inc AKRO

AKRO NASDAQ
AKRO
Akero Therapeutics, Inc NASDAQ
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals

AKRO Chart

Ideas

Top authors: AKRO
ProjectSyndicate
ProjectSyndicate Premium
Follow Following Unfollow
AKRO
AKRO
, 1WLong
AKRO: AKRO

AKRO

AKRO
AKRO
, 1DLong
AKRO: AKRO

Inverted Head and Shoulders....???

Strongly Positive Histological Data
AKRO
, 60
AKRO: Strongly Positive Histological Data

Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients 48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group 28% fibrosis improvement of at least two stages across all dose groups, with a...

AKRO 100% gains wait for pullback(STOCKS)
AKRO
, 1DLong
AKRO: AKRO 100% gains wait for pullback(STOCKS)

before we kick start the update. your upvotes/subs are appreciated. Why get subbed to to me on Tradingview? -15+ years real live trading experience -TOP Author on TradingView -professional chart break downs -key levels -no junk on my charts -frequent updates -covering FX/crypto/US stocks -24/7 uptime so constant updates So without further due. Keep it...

(AKRO) akero therapeutics daily chart review by projectsyndicate
AKRO
, 1DLong
AKRO: (AKRO) akero therapeutics daily chart review by projectsyndicate

long-term buy and hold from 18 target is +70% near 30. get ready to buy dips later in q1 2020.

HEY AKRO
AKRO
, 1DLong
AKRO: HEY AKRO

BASED ON MY TECHNICAL ANALYSIS IT'S PROBABLY THAT GO UP IN THE FUTURE

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Breaking news

More news